TrialsgrambetaRCTs are beautiful

SERAPHIN

2013

Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcome

In 742 patients with pulmonary arterial hypertension, macitentan reduced morbidity and mortality events compared with placebo.

Result

Efficacy: First morbidity or mortality eventHR 0.55

Below 1 favours macitentan, above 1 favours placebo.

Original publication
Subtopic
Endothelin antagonists
Design
Double-blind, event-driven RCT
Relevance
Important: one of several pillars.
Source
Pulido T, et al. N Engl J Med. 2013;369(9):809-818.doi 10.1056/NEJMoa1213917

Discussion & critique

First PAH trial powered for a long-term morbidity/mortality endpoint rather than 6-minute walk distance; it raised the evidentiary bar for the field.